tirzepatide weight loss study shows 47% greater vs. Wegovy Tirzepatide causes more weight loss

We conclude with a discussion of the knowledge gaps that must be addressed before incretin-based therapies can be properly deployed for maximum benefit in the treatment of obesity and T2DM

Nevertheless, a medical history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 constitutes a tirzepatide contraindication [14]

All prescriptions come from licensed 503A compounding pharmacies and are HSA/FSA eligible

Behuemn sits in the evidence-based middle: the same molecules the New England Journal trials used delivered with the clinical supervision that makes them safe, effective, and durable